Publications Archive - KalVista Pharmaceuticals

Showing 4 out of 4

Efficacy of plasma kallikrein inhibitors in plasma is dependent on the rate of formation of the enzyme-inhibitor complex.

De Donatis GM, Murugesan N, Duckworth E, Robson PA, Li L, Rushbrooke LJ, Feener EP and Hampton SL.
KININ 2018

KVD900 protects high molecular weight kininogen (HK) from ex vivo plasma kallikrein-mediated cleavage in plasma from patients with hereditary angioedema (HAE): Results from a semi-automated capillary-based immunoassay.

Feener EP, Murugesan N, Robson PA, Li L, Rushbrooke LJ, Thoonen R, De Donatis GM, Riedl M, Zuraw B, and Hampton SL.
EAACI 2018

A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema (#3464).

Murugesan N, Clermont AC, Rushbrooke LJ, Robson PA, Thoonen R, Pethen SJ, Hampton SL, and Feener EP.
ARVO 2018

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.

Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP and Feener EP.
Nature Medicine. 2007;13:181-8.
PMID:17259996

About

Science

Pipeline

Careers

Contact